Analyzing Ernexa Therapeutics (ERNA) and Its Peers

Ernexa Therapeutics (NASDAQ:ERNA) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Ernexa Therapeutics to similar businesses based on the strength of its valuation, dividends, analyst recommendations, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Ernexa Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Ernexa Therapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Insider and Institutional Ownership

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Ernexa Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	1	1	0	2.00
Ernexa Therapeutics Competitors	9838	15122	45436	1587	2.54

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,503.42%. As a group, “Biotechnology” companies have a potential upside of 102.45%. Given Ernexa Therapeutics’ higher probable upside, research analysts clearly believe Ernexa Therapeutics is more favorable than its competitors.

Risk and Volatility

Ernexa Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics’ competitors have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ernexa Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	-$14.08 million	-0.13
Ernexa Therapeutics Competitors	$734.01 million	$12.79 million	-15.19

Ernexa Therapeutics’ competitors have higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Ernexa Therapeutics competitors beat Ernexa Therapeutics on 8 of the 13 factors compared.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.